4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†

F Cardoso; E Senkus; A Costa; E Papadopoulos; M Aapro; F André; N Harbeck; B Aguilar Lopez; C H Barrios; J Bergh; L Biganzoli; C B Boers-Doets; M J Cardoso; L A Carey; J Cortés; G Curigliano; V Diéras; N S El Saghir; A Eniu; L Fallowfield; P A Francis; K Gelmon; S R D Johnston; B Kaufman; S Koppikar; I E Krop; M Mayer; G Nakigudde; B V Offersen; S Ohno; O Pagani; S Paluch-Shimon; F Penault-Llorca; A Prat; H S Rugo; G W Sledge; D Spence; C Thomssen; D A Vorobiof; B Xu; L Norton; E P Winer

doi:10.1093/annonc/mdy192

4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†

Ann Oncol. 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192.

Authors

F Cardoso¹, E Senkus², A Costa³, E Papadopoulos⁴, M Aapro⁵, F André⁶, N Harbeck⁷, B Aguilar Lopez⁸, C H Barrios⁹, J Bergh¹⁰, L Biganzoli¹¹, C B Boers-Doets¹², M J Cardoso¹³, L A Carey¹⁴, J Cortés¹⁵, G Curigliano¹⁶, V Diéras¹⁷, N S El Saghir¹⁸, A Eniu¹⁹, L Fallowfield²⁰, P A Francis²¹, K Gelmon²², S R D Johnston²³, B Kaufman²⁴, S Koppikar²⁵, I E Krop²⁶, M Mayer²⁷, G Nakigudde²⁸, B V Offersen²⁹, S Ohno³⁰, O Pagani³¹, S Paluch-Shimon³², F Penault-Llorca³³, A Prat³⁴, H S Rugo³⁵, G W Sledge³⁶, D Spence³⁷, C Thomssen³⁸, D A Vorobiof³⁹, B Xu⁴⁰, L Norton⁴¹, E P Winer⁴²

Affiliations

¹ European School of Oncology (ESO), European Society for Medical Oncology (ESMO) and Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal. Electronic address: fatimacardoso@fundacaochampalimaud.pt.
² European Society for Medical Oncology (ESMO) and Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
³ European School of Oncology, Milan, Italy.
⁴ Europa Donna Cyprus, Nicosia, Cyprus.
⁵ Oncology Department, Clinique de Genolier, Genolier, Switzerland.
⁶ Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
⁷ Breast Centre, Department of Obstetrics and Gynaecology, University of Munich (LMU), Munich, Germany.
⁸ Direction Office, ULACCAM (Union Latinoamericana Contra el Cáncer de la Mujer), Mexico DF, Mexico.
⁹ Department of Oncology, PURCS School of Medicine, Porto Alegre, Brazil.
¹⁰ Department of Oncology-Pathology, Karolinska Institute & University Hospital, Stockholm, Sweden.
¹¹ European Society of Breast Cancer Specialists (EUSOMA) and Department of Medical Oncology, Nuovo Ospedale di Prato - Istituto Toscano Tumori, Prato, Italy.
¹² CB Boers Organization, Wormer, The Netherlands.
¹³ Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation and Nova Medical School, Lisbon, Portugal.
¹⁴ Department of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA.
¹⁵ Department of Oncology, Vall d' Hebron University, Barcelona, Spain.
¹⁶ Division of Early Drug Development, Department of Oncology and Hemato-Oncology, European Institute of Oncology, University of Milano, Milano, Italy.
¹⁷ Gynaecology and Breast Department, Centre Eugène Marquis, Rennes, France.
¹⁸ Breast Center of Excellence, American University of Beirut Medical Center, Beirut, Lebanon.
¹⁹ Breast Cancer Department, Cancer Institute Ion Chiricuta, Cluj-Napoca, Romania.
²⁰ SHORE-C, Brighton & Sussex Medical School, University of Sussex, Brighton, UK.
²¹ Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
²² Medical Oncology Department, BC Cancer Agency, Vancouver, Canada.
²³ Department of Medicine, The Royal Marsden, Sutton, UK.
²⁴ Department of Oncology, Sheba Medical Center, Ramat Gan, Israel.
²⁵ Department of Medical Oncology, Bombay Hospital Institute of Medical Sciences, Mumbai, India.
²⁶ Breast Oncology Center Dana-Farber Cancer Institute, Boston, USA.
²⁷ Advanced BC.org, New York, USA.
²⁸ Advocacy Department, UWOCASO (Uganda Women's Cancer Support Organization), Kampala, Uganda.
²⁹ European Society of Radiation Oncology (ESTRO) and Department of Experimental Clinical Oncology & Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
³⁰ Cancer Institute Hospital, Breast Oncology Centre, Tokyo, Japan.
³¹ Institute of Oncology of Southern Switzerland, Geneva University Hospitals, Swiss Group for Clinical Cancer Research (SAKK), International Breast Cancer Study Group (IBCSG), Bellinzona, Switzerland.
³² Oncology Institute, Shaare Zedek Medical Centre, Jerusalem, Israel.
³³ Department of Pathology, Centre Jean Perrin, Clermont-Ferrand Cedex, France.
³⁴ IDIBAPS (Institut d'Investigacions Biomèdiques August Pi iSunyer), Hospital Clínic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumor, Barcelona, Spain.
³⁵ Breast Oncology Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA.
³⁶ Oncology Division, Stanford University Medical Center, Stanford, USA.
³⁷ Policy Department, Breast Cancer Network Australia, Camberwell, VIC, Australia.
³⁸ Department of Gynaecology, Martin Luther University Halle-Wittenburg, Halle, Germany.
³⁹ Oncology Department, Sandton Oncology Centre, Johannesburg, South Africa.
⁴⁰ Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China.
⁴¹ Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York.
⁴² Dana-Farber Cancer Institute, Susan Smith Center for Women's Cancers, Breast Oncology Center, Boston, USA.

No abstract available

Publication types

Practice Guideline

MeSH terms

Biomarkers, Tumor / genetics
Biomarkers, Tumor / metabolism
Biopsy, Large-Core Needle
Breast / diagnostic imaging
Breast / pathology
Breast / surgery
Breast Neoplasms / diagnosis
Breast Neoplasms / pathology
Breast Neoplasms / therapy*
Chemoradiotherapy, Adjuvant / methods
Chemoradiotherapy, Adjuvant / standards
Clinical Trials as Topic
Consensus Development Conferences as Topic*
Europe
Evidence-Based Medicine / methods
Evidence-Based Medicine / standards
Female
Humans
Integrative Medicine / methods
Integrative Medicine / standards
Mastectomy / methods
Mastectomy / standards
Medical Oncology / methods
Medical Oncology / standards*
Neoadjuvant Therapy / methods
Neoadjuvant Therapy / standards
Neoplasm Staging
Societies, Medical / standards
Treatment Outcome

Substances

Biomarkers, Tumor

Grants and funding

P30 CA016086/CA/NCI NIH HHS/United States